Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial

RCT (n=695) found a greater reduction in HbA1c for exenatide weekly plus dapagliflozin vs exenatide weekly plus placebo or dapagliflozin plus placebo at week 104 (-1.70% vs -1.29%, p=0.007, and -1.70% vs -1.06%, p<0.001 respectively).


Diabetes Care